These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 8787889)

  • 21. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia.
    Bartoloni A; Strohmeyer M; Corti G; Buonomini MI; Franchino L; Romanelli G; Moretti AM; De Vizzi GB; Petraglia A; Mancini P; Atzeni R; Fogliani V; Giura R; Paradisi F
    Drugs Exp Clin Res; 1999; 25(6):243-52. PubMed ID: 10713862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit.
    Verwaest C;
    Clin Microbiol Infect; 2000 Jun; 6(6):294-302. PubMed ID: 11168137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of meropenem in animals, healthy volunteers, and patients.
    Moon YS; Chung KC; Gill MA
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S249-55. PubMed ID: 9126700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients--a comparison of meropenem and imipenem/cilastatin. COPD Study Group.
    Hamacher J; Vogel F; Lichey J; Kohl FV; Diwok K; Wendel H; Lode H
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():121-33. PubMed ID: 8543488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial.
    Nakane T; Tamura K; Hino M; Tamaki T; Yoshida I; Fukushima T; Tatsumi Y; Nakagawa Y; Hatanaka K; Takahashi T; Akiyama N; Tanimoto M; Ohyashiki K; Urabe A; Masaoka T; Kanamaru A;
    J Infect Chemother; 2015 Jan; 21(1):16-22. PubMed ID: 25239059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa.
    Kuti JL; Florea NR; Nightingale CH; Nicolau DP
    Pharmacotherapy; 2004 Jan; 24(1):8-15. PubMed ID: 14740783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants.
    Hornik CP; Herring AH; Benjamin DK; Capparelli EV; Kearns GL; van den Anker J; Cohen-Wolkowiez M; Clark RH; Smith PB;
    Pediatr Infect Dis J; 2013 Jul; 32(7):748-53. PubMed ID: 23838776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Formulary review of the carbapenems: comparison of imipenem/cilastatin and meropenem.
    Richerson MA; Ambrose PG; Quintiliani R; Nightingale CH
    Conn Med; 1998 Mar; 62(3):165-9. PubMed ID: 9573653
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical pharmacokinetics of an imipenem-cilastatin combination].
    Singlas E
    Presse Med; 1990 Apr; 19(13):598-605. PubMed ID: 2139939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation.
    Lomaestro BM; Drusano GL
    Antimicrob Agents Chemother; 2005 Jan; 49(1):461-3. PubMed ID: 15616337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study.
    Fabian TC; File TM; Embil JM; Krige JE; Klein S; Rose A; Melnick D; Soto NE
    Surg Infect (Larchmt); 2005; 6(3):269-82. PubMed ID: 16201937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of cross-reactivity to meropenem in a patient with an allergy to imipenem-cilastatin.
    Bauer SL; Wall GC; Skoglund KJ; Peters LK
    J Allergy Clin Immunol; 2004 Jan; 113(1):173-5. PubMed ID: 14713926
    [No Abstract]   [Full Text] [Related]  

  • 33. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group.
    Geroulanos SJ
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():191-205. PubMed ID: 8543495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic profiles of intravenous imipenem/cilastatin during slow hemodialysis in critically ill patients.
    Kihara M; Ikeda Y; Shibata K; Masumori S; Ebira H; Shiratori K; Ueda S; Takagi N; Umemura S; Shionoiri H
    Clin Nephrol; 1994 Sep; 42(3):193-7. PubMed ID: 7994939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients.
    Shah PM; Heller A; Fuhr HG; Walther F; Halir S; Schaumann R; Böhme A; Jung B; Köhler A; Lips-Schulte C; Stille W
    Infection; 1996; 24(6):480-4. PubMed ID: 9007599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.
    Fournier A; Eggimann P; Pagani JL; Revelly JP; Decosterd LA; Marchetti O; Pannatier A; Voirol P; Que YA
    Burns; 2015 Aug; 41(5):956-68. PubMed ID: 25678084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients.
    Cox CE; Holloway WJ; Geckler RW
    Clin Infect Dis; 1995 Jul; 21(1):86-92. PubMed ID: 7578765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical and pharmacokinetic study of imipenem/cilastatin in children and newborn infants].
    Bégué P; Quinet B; Baron S; Challier P; Fontaine JL; Lasfargues G
    Pathol Biol (Paris); 1989 May; 37(5):485-90. PubMed ID: 2674874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem.
    Wu Y; Chen K; Shi Z; Wang Q
    Curr Pharm Biotechnol; 2014; 15(8):685-90. PubMed ID: 25051950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.